Mankind Pharma Limited has informed the Exchange about Acquisition
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.4 pts less than Nifty Midcap 150 and 3.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mankind Pharma's board approved audited Q4 and FY25 results along with several governance and structural decisions on May 21, 2025. FY25 consolidated revenue from operations rose about 19% to INR 12,207 crore, with profit for the period at INR 2,011 crore and basic EPS of INR 49.28. Q4 revenue grew roughly 27% year-on-year to INR 3,079 crore, though Q4 net profit dipped to INR 425 crore from INR 477 crore a year ago. The board appointed a new secretarial auditor for five years, re-appointed cost auditors, increased corporate guarantees for two subsidiaries, and approved setting up a wholly owned subsidiary in Sri Lanka. Results reflect the full-quarter impact of the October 2024 Bharat Serums and Vaccines (BSV) acquisition (INR 13,768 crore deal, provisional goodwill of INR 6,473 crore), which lifted total assets to about INR 27,760 crore. The company also recognised a INR 150 crore capital gain from selling its non-core Mahananda Spa subsidiary to Chalet Hotels and flagged ongoing income-tax appellate proceedings involving disallowances of about INR 1,839 crore, which it believes will not have a material impact.
Strong top-line growth driven by the BSV acquisition, but margins are slightly softer and Q4 profit declined year-on-year; the higher debt from acquisition financing is being partly prepaid via asset sales and CP redemptions. Shareholders should watch for updates on the income-tax appeals and any further integration impact from BSV.